Dermata Therapeutics (DRMA) Projected to Post Earnings on Monday

Dermata Therapeutics (NASDAQ:DRMA) is expected to issue its results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter.

Dermata Therapeutics Stock Performance

DRMA opened at $1.25 on Monday. The company has a fifty day moving average of $1.86 and a two-hundred day moving average of $3.23. The stock has a market capitalization of $3.55 million, a price-to-earnings ratio of -0.16 and a beta of 0.60. Dermata Therapeutics has a fifty-two week low of $1.11 and a fifty-two week high of $23.70.

Institutional Trading of Dermata Therapeutics

A hedge fund recently bought a new stake in Dermata Therapeutics stock. Clear Street Group Inc. bought a new position in shares of Dermata Therapeutics, Inc. (NASDAQ:DRMA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned approximately 0.60% of Dermata Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 8.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on DRMA shares. Weiss Ratings restated a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday, December 29th. Wall Street Zen raised Dermata Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $10.00.

About Dermata Therapeutics

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.